NasdaqCM - Nasdaq Real Time Price USD

SciSparc Ltd. (SPRC)

0.3443

+0.0018

+(0.53%)

At close: May 9 at 4:00:00 PM EDT

0.3300

-0.01

(-4.15%)

After hours: May 9 at 7:38:28 PM EDT

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent appl

GlobeNewswire 16 days ago

CMND

SPRC
+0.53%
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office (“KIPO”). The patent application relates to a combination treat

GlobeNewswire 2 months ago

SPRC
+0.53%

CMND
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea’s official patent and intellectual property authority. The patent covers the Company’s innovative

GlobeNewswire 2 months ago

SPRC
+0.53%

CMND
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio Ltd. (“MitoCareX”), the Compa

GlobeNewswire 2 months ago

SPRC
+0.53%
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the “New Loan”). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui

GlobeNewswire 2 months ago

SPRC
+0.53%
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

Neve Yarak, Israel, Feb. 26, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for solar energy, energy battery storage and innovation for agri- tech, announced today that it has entered a definitive agreement to acquire MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting

GlobeNewswire 2 months ago

SPRC
+0.53%

NITO
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has reached an important settlement agreement (the “Settlement”) regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company’s former directors (the “

GlobeNewswire 2 months ago

SPRC
+0.53%
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to

GlobeNewswire 3 months ago

CMND

SPRC
+0.53%
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-

GlobeNewswire 3 months ago

SPRC
+0.53%
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s d

GlobeNewswire 3 months ago

SPRC
+0.53%
SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following initial in-vitro results. MitoCareX recently achieved positive results using pancreatic cancer cell lines. These findings build on MitoCareX’s earlier success in developing a computationally advanced drug discovery platform that virtually screened millions of small molecules, identifying several as potential anti-cancer treatme

TipRanks 3 months ago

SPRC
+0.53%
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman, is expanding its research and development efforts into pancreatic cancer following encouraging initial in-vitro results. MitoCareX, which focuses on drug

GlobeNewswire 4 months ago

SPRC
+0.53%
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

On Monday, SciSparc Ltd (NASDAQ:SPRC) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, t

Benzinga 4 months ago

SPRC
+0.53%
Sector Update: Health Care Stocks Edge Higher Premarket Monday

Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR

PREMIUM
MT Newswires 4 months ago

SPRC
+0.53%

GDTC
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-tre

GlobeNewswire 4 months ago

SPRC
+0.53%

CMND
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval

The approval is expected to be extended following the anticipated final consent from the Israeli police department.

Clinical Trials Arena 4 months ago

SPRC
+0.53%
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children with autism spectrum disorder ("ASD"). SCI-210 is a proprietary combi

GlobeNewswire 4 months ago

SPRC
+0.53%
SciSparc: AutoMax announces $13M first delivery of JAC vehicles

SciSparc (SPRC)announced that AutoMax Motors, an automotive importer and distributor in Israel with which the company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import and distribution operations, launched under agreements signed earlier this year with JAC Motors. The shipment follows regulato

TipRanks 4 months ago

SPRC
+0.53%
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment

SciSparc Ltd. (NASDAQ:SPRC) shares are rocketing on Thursday after it disclosed that AutoMax Motors Ltd., an Israeli automotive importer and distributor with which it has a merger agreement, has received its $13 million first delivery of JAC vehicles from Anhui Jianghuai Automobile Group Co., Ltd. (JAC Motors). This marks a key milestone in AutoMax’s direct import and distribution operations initiated earlier this year under agreements with JAC Motors. With regulatory approvals in place, AutoMax

Benzinga 4 months ago

SPRC
+0.53%
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s d

GlobeNewswire 4 months ago

SPRC
+0.53%

Performance Overview

Return	SPRC	S&P 500 (^GSPC)
YTD	-4.36%	-3.77%
1-Year	-73.10%	+8.55%
3-Year	-99.46%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SciSparc Ltd. (SPRC)

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc says MitoCareX expands research to pancreatic cancer

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Sector Update: Health Care Stocks Edge Higher Premarket Monday

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

IMCA renews SciSparc’s autism spectrum disorder therapy trial approval

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

SciSparc: AutoMax announces $13M first delivery of JAC vehicles

SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Performance Overview